Trevi Therapeutics (NASDAQ:TRVI) Receives "Buy" Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI - Free Report) in a report issued on Wednesday morning,Benzinga reports. They currently have a $21.00 price objective on the stock.

TRVI has been the topic of several other reports. B. Riley restated a "buy" rating and set a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. Needham & Company LLC restated a "buy" rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Finally, HC Wainwright upped their target price on Trevi Therapeutics from $6.00 to $7.50 and gave the company a "buy" rating in a report on Thursday, December 12th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $9.31.

Trevi Therapeutics Price Performance

Shares of TRVI stock traded down $0.04 during trading hours on Wednesday, reaching $4.03. The company had a trading volume of 500,890 shares, compared to its average volume of 711,778. The company has a market cap of $309.77 million, a price-to-earnings ratio of -9.16 and a beta of 0.87. Trevi Therapeutics has a 12 month low of $1.27 and a 12 month high of $4.68. The business has a fifty day simple moving average of $3.37 and a 200-day simple moving average of $3.13.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter last year, the company posted ($0.08) earnings per share. On average, equities research analysts expect that Trevi Therapeutics will post -0.49 earnings per share for the current year.

Institutional Trading of Trevi Therapeutics

Several hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets lifted its stake in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company's stock valued at $40,000 after buying an additional 6,764 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Trevi Therapeutics during the second quarter worth $61,000. Intech Investment Management LLC bought a new position in shares of Trevi Therapeutics in the third quarter worth $63,000. The Manufacturers Life Insurance Company grew its position in shares of Trevi Therapeutics by 87.6% in the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company's stock valued at $73,000 after purchasing an additional 11,450 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Trevi Therapeutics in the third quarter valued at $78,000. 95.76% of the stock is currently owned by institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.